DelveInsight’s Sialorrhea Pipeline Insights report provides a comprehensive outlook of the pipeline therapies that are in different clinical and pre-clinical stages of development, their launch, and how the market is expected to transform in the aftermath across the Sialorrhea domain.
The Sialorrhea Pipeline Analysis report offers a complete analysis of the therapeutics landscape by development stage, product type, route of administration, molecule type, and MOA for Sialorrhea emerging therapies. The pipeline report lays down the business opportunities, threats, prospective collaborations, strong competitors, and growth strategies.
Some of the key highlights from the Sialorrhea Pipeline report:
- At present, the treatment option for Sialorrhea includes a conservative approach (such as observation, postural changes, biofeedback) to more aggressive measures such as medication, radiation, and surgical therapy. Pharmacotherapy includes both prescribed and off-label medication.
- Myobloc is the first and only approved botulinum toxin type B for the treatment of cervical dystonia and chronic sialorrhea.
- Currently, some of the key pharmaceutical companies at the global level such as Orient Pharma, Nobelpharma, Aytu BioPharma, and many others are involved in the development of therapies for Sialorrhea.
- Some of the key therapies in the Sialorrhea Pipeline include OC oral solution, NPC-22, NT0502, and others. The launch of the therapies is expected to fuel the Sialorrhea market growth in the coming years.
- The off-label drugs in the Sialorrhea market are likely to observe a sharp decline in the coming years owing to the arrival of approved products. Since the majority of the Sialorrhea pipeline therapies are in the initial phase of development, the change in the therapeutics landscape is likely to take a few years.
Request for Sample @Sialorrhea Pipeline Insights and Outlook
Sialorrhea Pipeline Analysis: Drug Profile
- NT0502: NT0502 (N-desethyloxybutynin) is an oral, once- or twice-daily potential treatment to reduce chronic sialorrhea in patients with neurological and other conditions associated with drooling and excessive salivation as a result of limitations in a person’s ability to control and swallow oral secretions.
- NPC-22: Nobelpharma is developing NPC-22 for the treatment of hypersalivation in partnership with Kitasato University. The vaccine is currently in the Phase I stage of development.
- OC oral solution: Orient Pharma is working on OC oral solution. OC Oral solution is developed as a new treatment option that can be used to titrate saliva secretion rates to a level that is low enough to prevent unintentional loss (i.e. drooling) but not so low as to cause an uncomfortably dry mouth.
Dive deeper to know more @Sialorrhea therapeutics and drugs pipeline
Key Pipeline Therapies along with Companies
- OC oral solution: Orient Pharma
- NPC-22: Nobelpharma
- NT0502: Aytu BioPharma
And many others.
Sialorrhea Pipeline Therapeutics Assessment
- By Product Type
- Monotherapy
- Combination Therapy
- Mono/Combination.
- By Stage
- Discovery
- Pre-clinical
- Phase I
- Phase II
- Phase III
- Pre-registration
- By Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
- By Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Targets:
- Protease
- Immunomodulatory
- Multiple Kinase Inhibitor
- By Mechanism of Action
- Alpha 2 adrenergic receptor agonists
- Muscarinic receptor antagonists
Got queries? Reach out for more information @ Sialorrhea Drug Pipeline Assessment
Scope of the Report
- Coverage: Global
- Key Market Players: Orient Pharma, Nobelpharma, Neos Therapeutics, Aytu BioPharma, and many others.
- Key Pipeline Therapies: OC oral solution, NPC-22, NT0502, and many others.
Table of Content
| 1 | Report Introduction |
| 2 | Sialorrhea |
| 3 | Sialorrhea Current Treatment Patterns |
| 4 | Sialorrhea – DelveInsight’s Analytical Perspective |
| 5 | Therapeutic Assessment |
| 6 | Sialorrhea Late Stage Products (Phase-III) |
| 7 | Sialorrhea Mid Stage Products (Phase-II) |
| 8 | Early Stage Sialorrhea Products (Phase-I) |
| 9 | Sialorrhea Pre-clinical Products and Discovery Stage Products |
| 10 | Inactive Products |
| 11 | Dormant Products |
| 12 | Sialorrhea Discontinued Products |
| 13 | Sialorrhea Product Profiles |
| 14 | Sialorrhea Key Companies |
| 15 | Sialorrhea Key Products |
| 16 | Dormant and Discontinued Products |
| 17 | Sialorrhea Unmet Needs |
| 18 | Sialorrhea Future Perspectives |
| 19 | Sialorrhea Analyst Review |
| 20 | Appendix |
| 21 | Report Methodology |
Know more of what’s covered in the Sialorrhea Pipeline Assessment report
Key Questions Answered in the Sialorrhea Report
- What are the current options for Sialorrhea treatment?
- How many companies are developing therapies for the treatment of Sialorrhea?
- What are the principal therapies developed by these companies in the industry?
- How many therapies are developed by each company for the treatment of Sialorrhea?
- How many Sialorrhea emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Sialorrhea?
- Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact the Sialorrhea market?
Request for a Webex demo @Sialorrhea Drug Pipeline and get a walk-through of our report
Related Reports
Sialorrhea Market Insight
DelveInsight’s “Sialorrhea Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Sialorrhea market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
Sialorrhea Epidemiology Forecast
DelveInsight’s “Sialorrhea Epidemiology Forecast 2030” report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Sialorrhea in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Emphysema Market
DelveInsight’s “Emphysema Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Emphysema market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
H3N2 Infection Market
DelveInsight’s “H3N2 Infection Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the H3N2 Infection market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
Lennox Gastaut Syndrome Market
DelveInsight’s “Lennox Gastaut Syndrome Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Lennox Gastaut Syndrome market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
Ulcerative Colitis (UC) Market
DelveInsight’s “Ulcerative Colitis (UC) Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Ulcerative Colitis (UC) market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
Global Messenger RNA Market
DelveInsight’s ‘Global Messenger RNA (mRNA) based Vaccines and Therapeutics Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of the mRNA-based Vaccines and Therapeutics, along with its historical and forecasted epidemiology and market trends in North America, Europe, Asia, and ROW (rest of the world).
Healthcare Blogs By DelveInsight
- Age-Related Hearing Loss Devices Market
- Eye Disorders Prevalence and Key Companies
- Upcoming Devices in Medtech Market
- Key Companies in the Presbyopia Market
- Medical devices for Spinal Stenosis Treatment
- Spinal Stenosis Devices Key Companies
- Adult-Onset Still’s Disease Market Trends
- Key Companies in Bone Cancer Market
- Elastomeric Pump Market
- Key Companies in the Endoscopy Fluid Management Systems Market
- Migraines Therapeutics Market
- Pacemakers Pipeline Key Companies
- Clinical Development of Aducanumab
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect With Us at LinkedIn | Facebook | Twitter
Contact Information:
Shruti Thakur
+1(919)321-6187
info@delveinsight.com
The post Sialorrhea Therapeutics Landscape Anticipated to Transform with the Approval of Pipeline Therapies by Key Players including Orient Pharma, Nobelpharma, and Aytu BioPharma appeared first on Financial Market Brief.